OSL •
Healthcare •
Biotechnology •
Quote as of 06/10/2026 13:27
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeOSL
Market Capitalization318.92 mln
Float1,039 mln
Earnings Date06/24/2026
Piotroski F-Score
4
/ 9
Borderline
Beneish M-Score
-1.81
Caution advised
Relative Strength
72
/ 100
Outperforming
Debt / Equity
0.00
Debt-free
ROE
-12.68
Negative
Dividend Yield
0.00%
No dividend
Business Description
SoftOx Solutions AS is a Norwegian pharmaceutical company focused on developing new products to prevent and treat infections. Its lead product, SoftOx Inhalation Solution, is currently in Phase II clinical trials for treating ventilator-associated pneumonia and other airway infections. The company is also working on a broader range of antimicrobial treatments designed to fight bacteria, viruses, and fungi. Founded in 2012, SoftOx is based in Fornebu, Norway.
